A possible therapeutic strategy would be to use activators or inhibitors of TEAD and REST69–71 to drive the cells to a non-NE fate or lock the cells in a NE fate in combination with other therapies, for example ASCL1 inhibitors72 or Notch pathway regulators17,56 that exploit differential vulnerabilities of the various cell states in SCLC. Here, ASCL1 is linked to small cell lung carcinoma.